Cytochrome P450 (CYP) (CYP)

Cytochrome P450 (CYP) enzymes are a superfamily of heme-containing proteins primarily located in the liver that are responsible for the oxidative metabolism of approximately 75% of clinical drugs (Guengerich, 2008). These enzymes facilitate the Phase I metabolism of both endogenous substances, such as steroids and fatty acids, and exogenous xenobiotics. In the context of imagabalin (PD-0332334), a ligand for the alpha-2-delta subunit of voltage-gated calcium channels, these enzymes are evaluated for their potential role in drug-drug interactions. Clinical and in vitro studies have demonstrated that imagabalin is primarily excreted unchanged in the urine and does not significantly interact with major hepatic CYP isoforms, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (Bockbrader et al., 2010). This lack of interaction suggests that imagabalin has a low potential for metabolic drug-drug interactions, distinguishing it from many other centrally acting agents. Consequently, the hepatic cytochrome P450 system does not play a major role in the clearance or clinical pharmacology of imagabalin. Genetic polymorphisms in these enzymes can lead to significant inter-individual variability in drug response and toxicity for other medications, but this is not a concern for imagabalin due to its renal clearance pathway.

Other names

CYP450Cytochrome P450 monooxygenaseHeme-thiolate proteinMicrosomal monooxygenase

Cytochrome P450 enzymes catalyze the monooxygenation of substrates, incorporating one atom of molecular oxygen into the substrate and reducing the other to water, typically using NADPH as an electron donor.